Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Treasury Shares (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Treasury Shares for 11 consecutive years, with $24150.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares fell 70.35% to $24150.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24150.0 through Dec 2025, down 70.35% year-over-year, with the annual reading at $24150.0 for FY2025, 70.35% down from the prior year.
  • Treasury Shares hit $24150.0 in Q4 2025 for Seres Therapeutics, down from $100824.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $4.2 million in Q1 2023 to a low of $24150.0 in Q4 2025.
  • Historically, Treasury Shares has averaged $1.7 million across 5 years, with a median of $1.6 million in 2022.
  • Biggest five-year swings in Treasury Shares: surged 11203.92% in 2021 and later plummeted 98.66% in 2025.
  • Year by year, Treasury Shares stood at $734755.0 in 2021, then soared by 110.89% to $1.5 million in 2022, then soared by 117.99% to $3.4 million in 2023, then tumbled by 97.59% to $81459.0 in 2024, then crashed by 70.35% to $24150.0 in 2025.
  • Business Quant data shows Treasury Shares for MCRB at $24150.0 in Q4 2025, $100824.0 in Q3 2025, and $51199.0 in Q2 2025.